ACIU
AC Immune
AC Immune is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Company Sector
Novel Therapies
56 companies tagged with Novel Therapies.
Novel Therapies groups companies pursuing newer or less established treatment strategies that fall outside traditional small-molecule or standard biologic categories. It is a broad innovation bucket that often overlaps with cell therapy, gene therapy, and next-generation immunotherapy.
ADAP
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
AIM
AIM ImmunoTech
AIM ImmunoTech is an immunology-oriented biopharmaceutical company focused on inflammatory and immune-mediated disease programs, where each new data point can reshape expectations for the pipeline and the next catalyst window.
ALLO
Allogene Therapeutics
Allogene Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
ALPN
Alpine Immune Sciences
Alpine Immune Sciences is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
ALT
Altimmune
Altimmune is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
AMGN
Amgen Inc.
Amgen is a large-cap biopharmaceutical company with a commercial base spanning oncology, inflammation, bone health, cardiovascular disease, and rare disease. Investors follow the stock for the mix of marketed products, late-stage pipeline optionality, and recurring regulatory or launch milestones.
AUTL
Autolus Therapeutics plc
Autolus Therapeutics plc is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
AVCO
Avalon GloboCare
Avalon GloboCare is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
BCLI
Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics is a cell therapy company focused on translating complex living-cell science into clinically meaningful treatments for hard-to-treat diseases. Investors usually watch how the platform converts data, manufacturing readiness, and launch execution into a durable oncology or specialty franchise.
CLBS
Caladrius Biosciences
Caladrius Biosciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
CRGX
CARGO Therapeutics
CARGO Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
RNAC
Cartesian Therapeutics
Cartesian Therapeutics is a cell therapy company focused on translating complex living-cell science into clinically meaningful treatments for hard-to-treat diseases. Investors usually watch how the platform converts data, manufacturing readiness, and launch execution into a durable oncology or specialty franchise.
CELG
CELG
CELG is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
CRSP
CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company with exposure to cell therapy and genetic medicine. Investors watch the company for how its editing platform broadens beyond the first commercial and clinical milestones.
EYEN
Eyenovia
Eyenovia is an ophthalmology-focused biopharmaceutical company centered on eye-disease programs where clinical validation and specialty adoption drive the narrative.
EYPT
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals is an ophthalmology-focused biopharmaceutical company centered on eye-disease programs where clinical validation and specialty adoption drive the narrative.
GILD
Gilead Sciences
Gilead Sciences is a large-cap biopharmaceutical company with a commercial base anchored by antivirals and a growing set of oncology and inflammation programs. Investors track the balance between cash flow strength, launch execution, and pipeline replacement.
GRCL
Gracell Biotechnologies
Gracell Biotechnologies is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
GRPH
Graphite Bio
Graphite Bio is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
BEAT
HeartBeam
HeartBeam is a cardiometabolic biopharmaceutical company focused on long-duration disease areas where efficacy, access, and long-term adoption all matter to investors.
HSCS
HeartSciences
HeartSciences is a cardiometabolic biopharmaceutical company focused on long-duration disease areas where efficacy, access, and long-term adoption all matter to investors.
FIXX
Homology Medicines
Homology Medicines is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
IMRX
Immuneering
Immuneering is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
IMCR
Immunocore Holdings plc
Immunocore Holdings plc is an immunology-oriented biopharmaceutical company focused on inflammatory and immune-mediated disease programs, where each new data point can reshape expectations for the pipeline and the next catalyst window.
IMGN
ImmunoGen
ImmunoGen is an immunology-oriented biopharmaceutical company focused on inflammatory and immune-mediated disease programs, where each new data point can reshape expectations for the pipeline and the next catalyst window.
IMNM
Immunome
Immunome is an immunology-oriented biopharmaceutical company focused on inflammatory and immune-mediated disease programs, where each new data point can reshape expectations for the pipeline and the next catalyst window.
IMVT
Immunovant
Immunovant is an immunology-oriented biopharmaceutical company focused on inflammatory and immune-mediated disease programs, where each new data point can reshape expectations for the pipeline and the next catalyst window.
TIL
Instil Bio
Instil Bio is a cell therapy company focused on translating complex living-cell science into clinically meaningful treatments for hard-to-treat diseases. Investors usually watch how the platform converts data, manufacturing readiness, and launch execution into a durable oncology or specialty franchise.
NTLA
Intellia
Intellia Therapeutics is a gene-editing company focused on in vivo CRISPR-based medicines. Investors watch how the platform translates into durable clinical proof, delivery confidence, and a broader pipeline.
IOVA
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics is a commercial-stage cell therapy company focused on tumor-infiltrating lymphocyte, or TIL, therapies for solid tumors. The company's story is centered on turning a complex personalized treatment approach into a scalable oncology franchise, with investors watching launch execution, adoption, and the broader expansion of the TIL platform.
KYTX
Kyverna Therapeutics
Kyverna Therapeutics is an RNA medicines company focused on using nucleic-acid based approaches to address disease at the source. Investors usually watch platform progress, clinical translation, and whether the company can convert molecular science into a broader pipeline.
LEGN
Legend Biotech Corporation
Legend Biotech is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
LCTX
Lineage Cell Therapeutics
Lineage Cell Therapeutics is a cell therapy company focused on translating complex living-cell science into clinically meaningful treatments for hard-to-treat diseases. Investors usually watch how the platform converts data, manufacturing readiness, and launch execution into a durable oncology or specialty franchise.
LYEL
Lyell Immunopharma
Lyell Immunopharma is an immunology-oriented biopharmaceutical company focused on inflammatory and immune-mediated disease programs, where each new data point can reshape expectations for the pipeline and the next catalyst window.
MLTX
MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is an immunology-oriented biopharmaceutical company focused on inflammatory and immune-mediated disease programs, where each new data point can reshape expectations for the pipeline and the next catalyst window.
EYE
National Vision
National Vision is an ophthalmology-focused biopharmaceutical company centered on eye-disease programs where clinical validation and specialty adoption drive the narrative.
NAUT
Nautilus Biotechnology
Nautilus Biotechnology is a cell therapy company focused on translating complex living-cell science into clinically meaningful treatments for hard-to-treat diseases. Investors usually watch how the platform converts data, manufacturing readiness, and launch execution into a durable oncology or specialty franchise.
NEXI
NexImmune
NexImmune is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
NKTX
Nkarta
Nkarta is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
NKGN
NKGen Biotech, Inc.
NKGen Biotech is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
OMED
OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
PMCB
PharmaCyte Biotech
PharmaCyte Biotech is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
PSTV
PLUS THERAPEUTICS, Inc.
PLUS THERAPEUTICS is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
PGEN
Precigen
Precigen is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
SNY
Sanofi
Sanofi is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
SRPT
Sarepta Therapeutics
Sarepta Therapeutics is a genetic medicines company focused on neuromuscular disease, with investors watching how its RNA and gene-therapy programs translate into durable clinical and commercial value.
SELB
Selecta
Selecta is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
SGTX
Sigilon Therapeutics
Sigilon Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
SQZ
SQZ Biotech
SQZ Biotech is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
TCMD
Tactile Systems Technology, Inc.
Tactile Systems Technology is a cell therapy company focused on translating complex living-cell science into clinically meaningful treatments for hard-to-treat diseases. Investors usually watch how the platform converts data, manufacturing readiness, and launch execution into a durable oncology or specialty franchise.
TRML
Talaris Therapeutics
Talaris Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
THAR
Tharimmune
Tharimmune is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
VCEL
Vericel Corp
Vericel Corp is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
VERV
Verve Therapeutics
Verve Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
XBIO
Xenetic
Xenetic is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.